



Markets
/
Stocks
/
nasdaq-biib
/

Biogen Inc

BIIB

View Detailed Chart

118.840USD

-0.670-0.56%

Close 04/25, 16:00（ET）Quotes delayed by 15 min

17.31BMarket Cap

10.61P/E TTM



Biogen Inc

118.840

-0.670-0.56%

Company

Intraday

30m

Today

-0.56%

5 Days

+0.19%

1 Month

-13.31%

6 Months

-34.59%

Year to Date

-22.29%

1 Year

-43.11%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 37 analysts

BUY

Current Rating

188.947

Target Price

58.99%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

160

Total

Median

Average

Company name

Ratings

Analysts

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

BioMarin Pharmaceutical Inc

BMRN

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(5)

Neutral(4)

Buy(3)

Indicators

Sell(1)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

1.700

Neutral

RSI(14)

40.350

Neutral

STOCH(KDJ)(9,3,3)

65.484

Neutral

ATR(14)

5.068

Low Volatility

CCI(14)

54.755

Neutral

Williams %R

35.894

Buy

TRIX(12,20)

-0.730

Sell

StochRSI(14)

85.023

Overbought

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

118.380

Buy

MA10

117.721

Buy

MA20

121.756

Sell

MA50

135.071

Sell

MA100

148.835

Sell

MA200

179.366

Sell

News

More news coming soon, stay tuned...

Company

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Company codeBIIB

CompanyBiogen Inc

CEOMr. Christopher A. (Chris) Viehbacher

Websitehttps://www.biogen.com/